Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Launched by KAFRELSHEIKH UNIVERSITY · Sep 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how effective and safe it is to use a combination of aspirin with either ticagrelor or clopidogrel in patients who have had a minor stroke or a transient ischemic attack (TIA) caused by a blockage in a large blood vessel. The trial is specifically focused on patients who are receiving treatment for the first time within 24 hours of their stroke or TIA. Researchers want to see if a 180 mg dose of ticagrelor works better than a 300 mg dose of clopidogrel in helping patients recover and preventing future strokes.

To be eligible for this trial, participants must be between 18 and 75 years old and must have experienced their first large-vessel minor ischemic stroke or TIA. They cannot have received certain treatments or have specific health conditions, like a history of seizures or serious organ failure. If you or a family member are considering participation, you can expect regular follow-ups for at least 90 days to monitor your health and any side effects from the medications. This study is actively recruiting participants of all genders, aiming to gather important data that could help improve treatment options for stroke patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • the investigators included both genders with eligible ages ranging between 18-75 years, with the first-ever presentation with large-vessel minor ischemic stroke or TIA who received antiplatelet treatment within the first 24 hours of the onset of ischemic stroke. Patients are not eligible for rt-PA treatment
• Exclusion Criteria:
• • - The investigators excluded patients who had not been followed up on for 90 days after enrollment, those with NIHSS \< 5 or who had rapidly resolving symptoms before imaging results, and patients with a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis, history of head trauma with a residual neurological deficit).
• • The investigators excluded patients who had clinical seizures at the onset of their stroke, as well as those who had symptoms of any major organ failure, active malignancies, or an acute myocardial infarction within the previous six weeks, and those who were on warfarin, regular ticagrelor during the week before admission, or chemotherapy within the previous year.
• • The investigators excluded patients with active peptic ulcers, GIT surgery, bleeding history within the last year, and those with a history of major surgery within the last three months.
• • The investigators ruled out our trial patients who had a known allergy to the study drugs and those with INR \> 1.4 or P.T. \>18 or blood glucose level \< 50 or \> 400 mg/DL or blood pressure \< 90/60 or \> 185/110 mmHg on admission or Platelets \< 100,000.
• • The investigators excluded pregnant and lactating patients and those with stroke due to venous thrombosis and stroke following cardiac arrest or profuse hypotension ineligible for our trial.
• • Patients with contraindications to the study drugs were excluded.